Last reviewed · How we verify
ERY001
ERY001 encapsulates chemotherapeutic agents within red blood cells to enhance their delivery to tumors while reducing systemic toxicity.
ERY001 encapsulates chemotherapeutic agents within red blood cells to enhance their delivery to tumors while reducing systemic toxicity. Used for Advanced solid tumors, including colorectal and pancreatic cancer.
At a glance
| Generic name | ERY001 |
|---|---|
| Also known as | L asparaginase encapsulated in erythrocytes |
| Sponsor | ERYtech Pharma |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This approach leverages the natural properties of red blood cells to protect the encapsulated drugs from degradation and clearance, allowing for targeted release in hypoxic tumor environments where the drug is most needed.
Approved indications
- Advanced solid tumors, including colorectal and pancreatic cancer
Common side effects
- Fatigue
- Nausea
Key clinical trials
- Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) (PHASE2, PHASE3)
- GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (PHASE2, PHASE3)
- Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERY001 CI brief — competitive landscape report
- ERY001 updates RSS · CI watch RSS
- ERYtech Pharma portfolio CI